Neovasc (Neovasc) EV-to-EBITDA : -1.80 (As of Apr. 26, 2024)

View and export this data going back to 2008. Start your Free Trial

What is Neovasc EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Neovasc's enterprise value is $70.80 Mil. Neovasc's EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 was $-39.34 Mil. Therefore, Neovasc's EV-to-EBITDA for today is -1.80.

The historical rank and industry rank for Neovasc's EV-to-EBITDA or its related term are showing as below:

NVCN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -846.76 Med: -1.52 Max: 0.88
Current: -1.8

During the past 13 years, the highest EV-to-EBITDA of Neovasc was 0.88. The lowest was -846.76. And the median was -1.52.

NVCN's EV-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 15.18 vs NVCN: -1.80

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Neovasc's stock price is $30.03. Neovasc's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $-15.080. Therefore, Neovasc's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Neovasc EV-to-EBITDA Historical Data

The historical data trend for Neovasc's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neovasc EV-to-EBITDA Chart

Neovasc Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-EBITDA

Get a 7-Day Free Trial

-0.21

-1.67

-0.85

0.46

-0.78

Neovasc Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
EV-to-EBITDA	Get a 7-Day Free Trial															0.46	0.07	0.28	-	-0.78

Competitive Comparison of Neovasc's EV-to-EBITDA

For the Medical Devices subindustry, Neovasc's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neovasc's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neovasc's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Neovasc's EV-to-EBITDA falls into.

Neovasc EV-to-EBITDA Calculation

Neovasc's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	70.795	/	-39.339
	=	-1.80

Neovasc's current Enterprise Value is $70.80 Mil.
Neovasc's EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.34 Mil.

Neovasc (NAS:NVCN) EV-to-EBITDA Explanation

Neovasc's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	30.03	/	-15.080
	=	At Loss

Neovasc's share price for today is $30.03.
Neovasc's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.080.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Neovasc EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Neovasc's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Neovasc (Neovasc) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neovasc Inc (NAS:NVCN) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

13562 Maycrest Way, Suite 5138, Richmond, BC, CAN, V6V 2J7

Website

https://www.neovasc.com

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.